In vivo, the pharmacologic inhibition of PIM kinases decreased tumor growth in mice implanted with hepatoblastoma SCLCCs, with 57% of the tumors completely regressing, providing further evidence that PIM inhibition decreases hepatoblastoma stemness [100]. Here, PIM1 is linked to hepatoblastoma.